ASO

Rapid Flu Tests May Prove Especially Helpful This Season

On October 5, Chiron Corporation notified the CDC that none of its influenza vaccine (Fluvirin) would be available for distribution in the United States for the current influenza season. In the wake of this sudden removal of nearly half of the anticipated American vaccine supply, medical officials and the general public have grown increasingly alarmed about the scarcity of vaccine and the ris...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

Data Show FluMist May Reduce Seasonal Influenza Burden Among Children in School, Daycare Settings

New Economic Analyses of School and Daycare Study Outcomes SuggestVaccinating Against Influenza May Produce Cost Savings forCommunity at Large TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc.announced today research results showing that use of FluMist(R)(Influenza Virus Vaccine Live, Intranasal) in daycare and schoolsettings may help reduce the burden of seasona...

Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis

DURHAM, N.C.--(BUSINESS WIRE)--May 8, 2007 - InspirePharmaceuticals, Inc. (NASDAQ: ISPH) today announced results of aPhase 2 dose-ranging clinical trial comparing epinastine nasalspray and placebo in patients with seasonal allergic rhinitis. Forthe primary endpoint of improvement in total nasal symptom score,dose-related effects were observed in the trial, with the higherdose (0.1%) achievi...

Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine

SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a seasonal influenza vaccineformulated with the company's Vaxfectin(TM) adjuvant generated upto 60-fold higher antibody responses than an unformulated vaccineat the same dose in a recently completed study in mice. Formulationof sanofi pasteur's Fluzone(R) commercial vaccine withVaxfectin(TM) al...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

SUMMIT, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- CelgeneCorporation announced that the Eastern Cooperative Oncology Group(ECOG) has reported that its Data Monitoring Committee's (DMC)review of preliminary results from a large, randomized clinicaltrial for patients with newly diagnosed multiple myeloma has foundthat the use of a low dose of dexamethasone (Decadron) incombination wit...

Sarasota's Roskamp Institute Announces Positive Safety Data in Human Clinical Study for Alzheimer's Disease

And Japanese Study Suggests the Drug Improves Memory SARASOTA, Fla., March 22, 2007 /PRNewswire-FirstCall/ -- TheRoskamp Institute announced today that it has received positivepreliminary results in its major clinical study that is testing apromising new drug application for the treatment of Alzheimer'sdisease. The clinical study, which was first announced inSeptember, is the first human...